Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano: Clinical Trials & FDA Approval Profile

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (Global / Institutional) sponsors 29 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 11 active protocols (6 recruiting now), 5 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)3.5%
Median Closed Enrollment vs National (145 pts)44 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)29
Active Pipeline (Recruiting Now)11 (6)
Completed vs Stopped Early5 / 1 (3.5%)
Median Closed Actual Enrollment44 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Hospital Research SiteLocationShared Protocols
Fondazione IRCCS Istituto Nazionale dei TumoriMilan, MI17

Explore interactive annual charts and M&A subsidiary rollups in the Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI